Rooting for Scientific Advancements and Dreams for a Brighter Future
The Mogam Science Scholarship Foundation was created with the goal of encouraging and supporting young Korean scientists with scholarships and research grants to enable them to contribute to scientific and technological advancements in and outside Korea.
Document-based review
Interview
Final decision announced
※ Visit the Mogam Science Scholarship Foundation website for more information.
Following the company’s commitment to producing hemophilia treatments, the late founding chairman of GC Biopharma, Huh Young-Sup, founded the KHF in 1974. This initiative was undertaken as part of the company’s mission to serve Korean society, local communities, and fellow Koreans. The foundation provides a wide range of support to streamlining treatments and rehabilitation for persons struggling with hereditary hemophilia.
GC Biopharma, which began producing plasma derivatives in the early 1970s, turned its attention to the production of its hemophilia treatment (an anti-hemophilic factor or AHF) in 1974—the company’s determination to help hemophilia patients culminated in the creation of the KHF two decades later. GC Biopharma consulted with hemophilia organizations in the United States and other developed countries. It also sent a delegation to a hemophilia treatment center in Bonn, Germany, to survey its facilities and management. The company then teamed up with the mothers of hemophilic patients and the Hemophilic Patients Rehabilitation Association to launch the KHF.